<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110121</url>
  </required_header>
  <id_info>
    <org_study_id>CYN13-PICOREVLITE</org_study_id>
    <nct_id>NCT02110121</nct_id>
  </id_info>
  <brief_title>Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos</brief_title>
  <official_title>Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Picosure and Revlite Laser Systems for the
      treatment of unwanted tattoos.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tattoo clearance</measure>
    <time_frame>2 months post treatment last treatment</time_frame>
    <description>Clearance will be measured using a photographic scale. Photographs will be taken of the subjects at baseline and post treatment. The results will be compared to determine clearance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Unwanted Tattoos</condition>
  <arm_group>
    <arm_group_label>Picosure Laser System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Picosure Laser System for the Treatment of Unwanted Tattoos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revlite Laser System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revlite Laser System for the Treatment of Unwanted Tattoos</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picosure Laser System</intervention_name>
    <description>Picosure Laser System for the Treatment of Unwanted Tattoos</description>
    <arm_group_label>Picosure Laser System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revlite Laser System</intervention_name>
    <description>Revlite Laser System for the Treatment of Unwanted Tattoos</description>
    <arm_group_label>Revlite Laser System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy non-smoking (must have quit 6 months prior) male or female between 18 and
             65 years old.

          2. Is willing to consent to participate in the study.

          3. Is willing to comply with all requirements of the study including being photographed,
             following post treatment care and attending all treatment and follow up visits.

        Exclusion Criteria:

          1. The subject is female and pregnant, has been pregnant within the last 3 months, is
             currently breast feeding or planning a pregnancy during the study period.

          2. The subject is hypersensitive to light exposure OR takes photo sensitizing medication.

          3. The subject has active or localized systemic infections.

          4. The subject has a coagulation disorder or is currently using anti-coagulation
             medication (including but not limited to heavy aspirin therapy {greater than 81 mg per
             day}).

          5. The subject has any condition which, in the investigator's opinion, would make it
             unsafe for the subject to participate in this research study.

          6. The subject is currently enrolled in an investigational drug or device trial, or has
             received an investigational drug or been treated with an investigational device within
             3 months prior to entering this study.

          7. The subject has used Accutane within 6 months prior to enrollment.

          8. The subject has the need to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

          9. The subject has had prior treatment with parenteral gold therapy (gold sodium
             thiomalate).

         10. The subject has a history of keloid scar formation.

         11. The subject has evidence of compromised wound healing.

         12. The subject has a history of basal cell carcinoma, squamous cell carcinoma or
             melanoma.

         13. The subject has a history of immunosuppression/immune deficiency disorders (including
             HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune
             disorder.14. The subject has red tattoo ink allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cynosure Inc.</name>
      <address>
        <city>Westford</city>
        <state>Massachusetts</state>
        <zip>01886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

